Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma

被引:6
作者
Yamashita, Ryo [1 ]
Watanabe, Reiko [2 ]
Ito, Ichiro [2 ]
Shinsaka, Hideo [1 ]
Nakamura, Masafumi [1 ]
Matsuzaki, Masato [1 ]
Niwakawa, Masashi [1 ]
机构
[1] Shizuoka Canc Ctr, Div Urol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Pathol, Shizuoka, Japan
关键词
Urothelial carcinoma; Upper urinary tract; Nephroureterectomy; Bladder cancer recurrence; Tumor classification; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; RADICAL NEPHROURETERECTOMY; TUMOR LOCATION; MULTIFOCALITY; PREVENTION; IMPACT; TRIAL;
D O I
10.1007/s11255-017-1510-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients). We classified UUTUCs into three types: renal pelvic, short-length ureteral, and long-length ureteral cancer; the cutoff for categorizing short- versus long-length ureteral cancer was the median tumor length. Univariate and multivariate analyses with Cox regression methods were performed to calculate hazard ratios (HRs) for BC recurrence using nine clinical covariates, including our new pathologic classification. The median follow-up period for the survivors was 60 months (range 1-157 months). Of 99 patients, 36 (36%) had BC recurrence; of these 36 patients, 30 (85%) experienced recurrence within 2 years and 17 (47%) had invasive BC (ae<yen>pT1). Statistical analyses demonstrated that pathologic tumor type was the major significant risk factor for BC recurrence. Long-length (> 5 cm) ureteral cancer had the highest risk of BC recurrence compared to other tumor types (multivariate HR 2.1; 95% confidence interval 1.03-4.2). Our simple classification system based on the tumor's pathologic appearance is useful for predicting BC recurrence. Patients with long-length ureteral cancer have a high risk of BC recurrence.
引用
收藏
页码:425 / 430
页数:6
相关论文
共 17 条
[1]   The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy [J].
Chromecki, Thomas F. ;
Cha, Eugene K. ;
Fajkovic, Harun ;
Margulis, Vitaly ;
Novara, Giacomo ;
Scherr, Douglas S. ;
Lotan, Yair ;
Raman, Jay D. ;
Kassouf, Wassim ;
Bensalah, Karim ;
Weizer, Alon ;
Kikuchi, Eiji ;
Roscigno, Marco ;
Remzi, Mesut ;
Matsumoto, Kazumasa ;
Walton, Thomas J. ;
Pycha, Armin ;
Ficarra, Vincenzo ;
Karakiewicz, Pierre I. ;
Zigeuner, Richard ;
Pummer, Karl ;
Shariat, Shahrokh F. .
EUROPEAN UROLOGY, 2012, 61 (02) :245-253
[2]  
Green LF, 2002, AM JOINT COMMITTEE C
[3]   METACHRONOUS MULTIFOCAL DEVELOPMENT OF UROTHELIAL CANCERS BY INTRALUMINAL SEEDING [J].
HABUCHI, T ;
TAKAHASHI, R ;
YAMADA, H ;
KAKEHI, Y ;
SUGIYAMA, T ;
YOSHIDA, O .
LANCET, 1993, 342 (8879) :1087-1088
[4]   BLADDER-CANCER - FIELD VERSUS CLONAL ORIGIN [J].
HARRIS, AL ;
NEAL, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (11) :759-761
[5]   Risk factors for the development of bladder cancer after upper tract urothelial cancer [J].
Hisataki, T ;
Miyao, N ;
Masumori, N ;
Takahashi, A ;
Sasai, M ;
Yanase, M ;
Itoh, N ;
Tsukamoto, T .
UROLOGY, 2000, 55 (05) :663-667
[6]   Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial [J].
Ito, Akihiro ;
Shintaku, Ichiro ;
Satoh, Makoto ;
Ioritani, Naomasa ;
Aizawa, Masataka ;
Tochigi, Tatsuo ;
Kawamura, Sadafumi ;
Aoki, Hiroshi ;
Numata, Isao ;
Takeda, Atsushi ;
Namiki, Shunichi ;
Namima, Takashige ;
Ikeda, Yoshihiro ;
Kambe, Koichi ;
Kyan, Atsushi ;
Ueno, Seiji ;
Orikasa, Kazuhiko ;
Katoh, Shinnosuke ;
Adachi, Hisanobu ;
Tokuyama, Satoru ;
Ishidoya, Shigeto ;
Yamaguchi, Takuhiro ;
Arai, Yoichi .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1422-1427
[7]   Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract [J].
Ku, Ja Hyeon ;
Choi, Woo Seok ;
Kwak, Cheol ;
Kim, Hyeon Hoe .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (04) :383-387
[8]   Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract [J].
Matsui, Y ;
Utsunomiya, N ;
Ichioka, K ;
Ueda, N ;
Yoshimura, K ;
Terai, A ;
Arai, Y .
UROLOGY, 2005, 65 (02) :279-283
[9]  
Mostfi FK, 1999, INTERNATIONAL HISTOL
[10]   Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial) [J].
O'Brien, Tim ;
Ray, Eleanor ;
Singh, Rajinder ;
Coker, Bola ;
Beard, Ralph .
EUROPEAN UROLOGY, 2011, 60 (04) :703-710